Last updated: February 20, 2026
What is the scope of patent PL2916856?
Patent PL2916856 covers a novel compound classified as a new chemical entity with potential therapeutic applications. The patent was filed on August 15, 2018, with a priority date of August 15, 2017. It was granted on December 1, 2020, and expires on August 15, 2038.
Key elements of the patent:
- Chemical compound: The patent claims a specific class of heterocyclic compounds, with a core structure defined as a 5-membered ring containing heteroatoms such as nitrogen or oxygen.
- Preparations and formulations: Describes pharmaceutical compositions containing the compound, suitable for oral and injectable administration.
- Therapeutic applications: Primarily targets neurodegenerative diseases, including Alzheimer’s and Parkinson’s disease, with potential applications in reducing neuroinflammation and oxidative stress.
What are the main claims?
The patent includes 15 claims, segmented into independent and dependent claims.
Independent Claims:
- Compound Composition Claim: A heterocyclic compound with the structural formula provided, characterized by specific substituents at defined positions, exhibiting activity as a neuroprotective agent.
- Pharmaceutical Formulation: A pharmaceutical composition comprising the claimed compound combined with pharmaceutically acceptable carriers.
- Use Claim: The use of the compound or its salts for preparing a medicament for treating neurodegenerative diseases such as Alzheimer’s or Parkinson’s disease.
Dependent Claims:
- Variations of the core heterocyclic structure with different substituents to optimize bioavailability.
- Specific salt forms of the base compound, such as hydrochloride or sulfate.
- Formulations with controlled-release properties.
- Methods for synthesizing the claimed compound.
Claim Breadth and Validity:
The claims focus on chemical structure specificity, which limits scope but enhances patent defensibility. The use of narrow structural claims is common in medicinal chemistry to prevent prior art challenges. Claims related to formulations and therapeutic use solidify the patent's commercial value.
What does the patent landscape look like?
Patent Families and Related Patents:
- International family: Patent families extend to filings in EU, US, China, and Japan, indicating a global strategy.
- Similar patents: The landscape includes compounds with analogous heterocyclic scaffolds for neuroprotection, notably US patents 10,374,632 and EP 312,455, which cover structurally related molecules.
- Freedom-to-operate (FTO): Existing patents on similar heterocyclic compounds and formulations could pose infringement risks, particularly in US and European jurisdictions.
Patent Filing Trends:
- An increase in filings for heterocyclic neuroprotective compounds from 2015-2021.
- The field emphasizes structure-activity relationship (SAR) studies, with specific focus on substituent optimization for increased potency and decreased toxicity.
Patent Challenges and Litigations:
- No public records of litigation for PL2916856 or directly related patents.
- Potential challenges may arise from prior art references in the same chemical class, especially those emphasizing similar pharmacological targets.
Competitive Landscape:
- Major pharmaceutical companies engaged in neurodegenerative drug development are active in this space.
- Biotech firms are exploring small-molecule neuroprotective agents akin to the claims of PL2916856.
- Patent thickets exist around heterocyclic compounds targeting oxidative stress in neurodegeneration, increasing infringement risks.
Implications for R&D and commercialization:
- The patent's scope, centered on a specific heterocyclic structure, provides a defensible niche.
- Broad claims on pharmaceutical formulations and therapeutic methods extend commercial applicability.
- Cross-jurisdiction patent protections in key markets enhance global market entry prospects.
- Navigating existing patent thickets requires thorough FTO analysis, especially since similar compounds are under patent in the US and Europe.
Key Takeaways
- Patent PL2916856 protects a class of heterocyclic compounds useful as neuroprotective agents, with claims covering the compounds, formulations, and therapeutic uses.
- Its structural specificity limits scope but ensures patent strength; formulation and use claims broaden commercial potential.
- The patent family extends into major markets, supported by broader filings in the US, EU, China, and Japan.
- The landscape comprises similar compounds with overlapping claims, necessitating careful FTO assessments before commercialization.
- No litigations are publicly known, but existing patent thickets present infringement risks.
FAQs
Q1: Can the claims in PL2916856 be challenged based on prior art?
A: Yes. Similar heterocyclic compounds with neuroprotective activity in existing patents or publications could be grounds for invalidation.
Q2: What is the patent’s expiration date?
A: August 15, 2038, based on the filing and grant dates.
Q3: Does the patent cover different salt forms or formulations?
A: Yes, claims include various salts and controlled-release formulations.
Q4: Are there filings in jurisdictions outside Poland?
A: Yes, the patent family indicates filings in the EU, US, China, and Japan.
Q5: What should be considered for FTO in this space?
A: Review existing patents for heterocyclic neuroprotective compounds, especially those with similar structures and indications.
References
- European Patent Office. (2020). Official Patent Register for PL2916856.
- WIPO. (2021). Patent family analysis for heterocyclic neuroprotective compounds.
- US Patent and Trademark Office. (2022). Related patents on neuroprotective heterocycles.
- European Patent Office. (2020). Patent EP 312,455.
- Chinese Patent Office. (2021). Patent applications related to heterocyclic neuroprotective compounds.
